Pharmacopeia

CWP-0270

VERAPAMIL

Cardiovascular · Cardiovascular · Level 3

Core pharmacology

Legacy Cicm Level

Level 3

Introduction

Phenylalkylamine
(Non-dihydropyridine calcium channel blocker)

Synthetic papaverine derivative

Indications Uses

HTN
Angina
Paroxysmal SVT and AFib/Aflutter

Mechanism of action

Binds to V binding site of L-type channel.
Levoisomer: main effects (arterial vasodilation). Slows conduction through the AV and SA node to a greater extent than other CCBs.
Dextro: Only acts on fast sodium channels, accounting for local anesthetic effects (1.6x potent as procaine)

Protein binding

~90%

Volume of distribution

3.89 L/kg

Metabolism

Hepatic via multiple CYP isoenzymes, one active metabolite with 20% activity

Excretion

Urine (70% metab, 3% to 4% unchanged); feces (16%)

Half-life

3-7 hours

Route And Dose

40mgPO or 5-10mg IV.

Chemical Pharmaceutics

Racemic mixture.

Onset Peak Duration

on/ dur 1-2 hrs / 6-8 hrs (PO)

Cardiovascular · Cardiovascular

Class Group

(CCB) Ca channel blocker – Class I

Antiarrhythmic –
Vaughan Williams Class IV

Presentation

Racemic mixture. PO: 40-240mg. Also in combo w Trandolapril. IV Clear solution at 2.5mg/ml

Physiological effects

CVS: slow conduction of AP at SA and AV node, negatively inotropic, peripheral vasodilation (↓SVR), arrhythmia (heart block, VF in WPW). CNS: ↑CBF, may potentiate effects of depol/NDMBs. GIT - Constipn/Nausea

Adverse Effects Toxicity

Dizziness, nausea, flushing, postural hypotension.
in patients without CCF: ↑LV fn by improving ischemia. In pts with CCF: ↓contractility and LV fn. Should be avoided in pts with WPW- cause VT/VF.
Inhibits CYP3A4.

Absorption

PO/IV.
BA 20-25% Well absorbed with high fi¬rst pass metabolism
on/ dur 1-2 hrs / 6-8 hrs (PO)

Class Group

(CCB) Ca channel blocker – Class I

Antiarrhythmic –
Vaughan Williams Class IV

Introduction

Phenylalkylamine
(Non-dihydropyridine calcium channel blocker)

Synthetic papaverine derivative

Indications Uses

HTN
Angina
Paroxysmal SVT and AFib/Aflutter

Mechanism of action

Binds to V binding site of L-type channel.
Levoisomer: main effects (arterial vasodilation). Slows conduction through the AV and SA node to a greater extent than other CCBs.
Dextro: Only acts on fast sodium channels, accounting for local anesthetic effects (1.6x potent as procaine)

Adverse Effects Toxicity

Dizziness, nausea, flushing, postural hypotension.
in patients without CCF: ↑LV fn by improving ischemia. In pts with CCF: ↓contractility and LV fn. Should be avoided in pts with WPW- cause VT/VF.
Inhibits CYP3A4.

Absorption

PO/IV.
BA 20-25% Well absorbed with high fi¬rst pass metabolism
on/ dur 1-2 hrs / 6-8 hrs (PO)

Class Group

Antiarrhythmic –
Vaughan Williams Class IV

(CCB) Ca channel blocker – Class I

Presentation

PO: 40-240mg. Also in combo w Trandolapril. IV Clear solution at 2.5mg/ml

Physiological effects

CVS: slow conduction of AP at SA and AV node, negatively inotropic, peripheral vasodilation (↓ SVR), arrhythmia (heart block, VF in WPW). CNS: ↑ CBF, may potentiate effects of depol/NDMBs. GIT - Constipn/Nausea

Adverse Effects Toxicity

Dizziness, nausea, flushing, postural hypotension.
in patients without CCF: ↑ LV fn by improving ischemia. In pts with CCF: ↓ contractility and LV fn. Should be avoided in pts with WPW- cause VT/VF.
Inhibits CYP3A4.

Absorption

PO/IV.
BA 20-25% Well absorbed with high fi¬rst pass metabolism